|
CDC-501 therapy in relapsed or refractory multiple myeloma Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about CDC-501 therapy in relapsed or refractory multiple myeloma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. CDC-501 therapy in relapsed or refractory multiple myeloma Clinical research trials and CDC-501 therapy in relapsed or refractory multiple myeloma health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including CDC-501 therapy in relapsed or refractory multiple myeloma. CDC-501 therapy in relapsed or refractory multiple myeloma Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a CDC-501 therapy in relapsed or refractory multiple myeloma clinical trial. Test subjects typically receive the most expert healthcare available for their CDC-501 therapy in relapsed or refractory multiple myeloma condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > CDC-501 therapy in relapsed or refractory multiple myeloma  CDC-501 therapy in relapsed or refractory multiple myeloma
CDC-501 therapy in relapsed or refractory multiple myeloma
For Condition: Multiple Myeloma
Status: Completed
Sponsor(s): Celgene Corporation ,
Synopsis: The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Subject must be diagnosed with multiple myeloma (with measurable M-Protein in serum and/or urine), and be considered to have disease progression after at least two cycles of treatment or have relapsed after treatment. - Subject must understand and voluntarily sign an informed consent document. - Subject must not have received corticosteroids, other chemotherapy, thalidomide, or other investigational agents, within 21 days of baseline - ECOG (Zubrod) performance status of 0 to 2. - Subject must be able to adhere to the study visit schedule and other protocol requirements. - Women of childbearing potential (WCBP ) must have a negative serum or urine pregnancy test within 7 days of baseline. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug.
Total Enrollment: 60
Location and Contact Information:
St Vincent's Cancer Center
New York City, New York, 10011
United States
H Lee Moffit Cancer Center
Tampa, Florida, 33612
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
United States
Mayo Clinic
Rochester, Minnesota, 55902
United States
Additional Information:
Study ID Numbers: CC-5013-MM-007;
Study Start Date: April 2002
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00044018
Other Multiple Myeloma Studies:
1. Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide
2. Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients with Relapsed Multiple Myeloma
3. Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
4. Study of the Safety and Efficacy of an Investigational Drug in Adult Patients with Multiple Myeloma
5. Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Related Studies:
Other Multiple Myeloma Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
CDC-501 therapy in relapsed or refractory multiple myeloma
|
|
|
|
|
|
|
|
